Weight Loss Drug Manufacturers and Commercial Partners
The phrase “weight loss drug manufacturers” is often used broadly, but obesity-treatment industry records need more precise company roles. The company associated with a product may be its developer, regulatory sponsor, approval holder, labeler, physical manufacturer, commercial partner, distributor, or current corporate owner. Those roles can differ by product, market, date, and source.
The company answer depends on the record being checked. A label record, approval notice, clinical trial record, commercial announcement, shortage notice, or payer policy can point to different roles around the same product.
Product and company role map
Section titled “Product and company role map”This US-centered map uses official label, FDA, or regulatory source context where possible. It should not be read as a complete manufacturing-site, supply-chain, ownership, or distribution database.
| Product | Active ingredient | Company relationship | Role context | Source context |
|---|---|---|---|---|
| Wegovy | Semaglutide | Novo Nordisk-associated obesity product | Product, label, and sponsor context should be separated from physical manufacturing or supply claims. | Current DailyMed Wegovy label, FDA Wegovy 2021 approval notice |
| Zepbound | Tirzepatide | Eli Lilly-associated obesity product | FDA granted the original approval to Eli Lilly and Co.; the current label identifies Lilly USA, LLC as marketer. Broader manufacturing or distribution claims need separate sourcing. | FDA Zepbound 2023 approval notice, current DailyMed Zepbound label |
| Saxenda | Liraglutide | Novo Nordisk-associated liraglutide obesity product | Saxenda connects liraglutide to Novo Nordisk’s earlier GLP-1 obesity product history. | DailyMed Saxenda label search |
| Qsymia | Phentermine/topiramate | Qsymia-related company records | Labeler, approval-holder, corporate, and commercialization context should be checked against dated records before reuse. | DailyMed Qsymia label search |
| Contrave | Naltrexone/bupropion | Contrave-related company records | Contrave has a more complex commercialization history, so company-role claims should stay source-specific and dated. | DailyMed Contrave label search |
| Xenical | Orlistat | Orlistat-related prescription product records | Prescription product context should be kept separate from nonprescription orlistat records. | DailyMed Xenical label search |
| Alli | Orlistat | Orlistat-related nonprescription product records | Nonprescription channel context should not be collapsed into prescription product, reimbursement, or clinical-comparison claims. | DailyMed Alli label search |
Why manufacturer wording needs context
Section titled “Why manufacturer wording needs context”In ordinary use, “manufacturer” may mean the company that a reader associates with a drug. In regulatory and commercial records, the word can be too broad unless the source identifies the exact role.
| Role | What it usually identifies | Why it matters |
|---|---|---|
| Developer | The organization associated with discovery or clinical development | Development history may differ from current product ownership or commercialization |
| Sponsor or applicant | The company named in a regulatory submission or approval context | Regulatory responsibility is jurisdiction- and date-specific |
| Approval holder or authorization holder | The entity responsible for an approved product in a market | Authorization can differ by country, acquisition history, or product version |
| Labeler | The company named in a label or listing record | Labeler records do not automatically describe all manufacturing, distribution, or payer relationships |
| Physical manufacturer | The entity or facility involved in making the product | Manufacturing-site and supply-chain claims require specific sourcing |
| Commercial partner or distributor | A company involved in marketing, sales, distribution, or channel access | Commercial roles can vary by market and can change over time |
Anchor companies in incretin-based obesity treatment
Section titled “Anchor companies in incretin-based obesity treatment”Novo Nordisk is closely associated with Wegovy and Saxenda in US obesity-treatment records. Wegovy connects semaglutide to the modern GLP-1 receptor agonist obesity market, while Saxenda connects liraglutide to an earlier GLP-1 obesity product record. Novo Nordisk also appears in obesity-treatment research through related diabetes products, manufacturing-capacity discussion, and pipeline programs, but each product, label, and supply claim needs its own source context.
Source context: DailyMed Wegovy label search, DailyMed Saxenda label search, FDA Wegovy cardiovascular-risk indication notice, March 8, 2024
Eli Lilly is closely associated with Zepbound, the tirzepatide product approved by FDA on November 8, 2023. Lilly’s obesity-treatment record also connects to Mounjaro, approved oral product Foundayo, and investigational retatrutide, but those relationships should remain product-, indication-, trial-, date-, and source-specific.
Source context: Eli Lilly company record, current DailyMed Zepbound label, FDA Foundayo approval notice, ClinicalTrials.gov TRIUMPH-1 record
Older oral and non-incretin product records
Section titled “Older oral and non-incretin product records”Qsymia, Contrave, Xenical, and Alli keep the company database from becoming only an incretin-market map. They connect obesity-treatment research to older oral products, fixed-dose combinations, lipase inhibition, prescription and nonprescription channels, and more complex commercialization histories.
These records are especially sensitive to role wording. A product may have an original developer, a labeler, an approval-holder record, a current commercial arrangement, and a separate manufacturing or supply-chain context. A single company name should not be treated as a complete answer unless the source identifies the role being claimed.
Source context: DailyMed Qsymia label search, DailyMed Contrave label search, DailyMed Xenical label search, DailyMed Alli label search
What not to infer
Section titled “What not to infer”A company associated with a drug is not necessarily the physical manufacturer of every presentation, the current distributor in every market, the payer-access decision-maker, or the source of stable supply. FDA approval does not establish launch timing, insurance coverage, reimbursement, pharmacy availability, shortage status, or clinical suitability.
Manufacturer and commercial partner records should be read with active ingredient, brand, and product distinctions, regulatory status distinctions, and market access context.